Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a $715 price target.
The rating update came after Eli Lilly and Company posted its fiscal Q2 2025 earnings the same day, with revenue growing 38% to $15.56 billion, driven primarily by volume growth from Zepbound and Mounjaro.
Eli Lilly and Company also raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion, taking it to the $60 billion to $62 billion range. It also raised its reported EPS guidance to be in the $20.85 to $22.10 range.
Eli Lilly and Company develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
